Mazdutide, a once-weekly injectable medication imitating a fullness-signaling gut hormone and an energy-releasing hormone, is approved only in China for weight management and type 2 diabetes. Evidence for weight and waist loss, lower blood sugar and cholesterol is strong. Main costs are frequent stomach and bowel side effects and a higher resting heart rate. Weight partly returns after stopping. Trials are short and nearly all company-funded; long-term safety is unknown. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; track percent change from own baseline | Expected to change |
| Lean mass (DEXA) | No established target; track lean-mass change from own baseline | Expected to change (safety-relevant) |
| HbA1c | 4.0–5.6% (standard reference range) | Expected to change |
| LDL cholesterol | No established target; track percent change from own baseline | Expected to change |
| Triglycerides | No established target; track percent change from own baseline | Expected to change |
| ALT | 7–55 U/L (standard reference range) | Safety check and expected to change |
| Lipase | Within the laboratory's upper limit of normal (standard reference range) | Safety check |
| Serum uric acid | 3.5–7.2 mg/dL (standard reference range) | Expected to change |
| Resting heart rate | 60–100 beats per minute (standard reference range) | Safety check |
| Blood pressure | No established target; track change from own baseline | Expected to change |
| eGFR | No established target; track change from own baseline | Safety check |
Cadence: Weekly weight and resting heart rate during escalation; blood tests 4 weeks after reaching maintenance dose, then every 3–6 months in the first year and every 6–12 months thereafter; DEXA scan at 6–12 months.